NCT03229200 2025-10-30
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Pharmacyclics Switzerland GmbH
Phase 4 Active not recruiting
Pharmacyclics Switzerland GmbH
Eli Lilly and Company
Peter MacCallum Cancer Centre, Australia